Diagnostic performance of multiparametric MRI in the evaluation of treatment response in glioma patients at 3T
J Liu, C Li, Y Chen, X Lv, Y Lv, J Zhou… - Journal of Magnetic …, 2020 - Wiley Online Library
… , rCBF (e), and APTw (f) maps. Multiparametric MR indices were … of a representative patient
confirmed as treatment effects. Briefly… displays hyperintense in the ADC map. Meanwhile, the …
confirmed as treatment effects. Briefly… displays hyperintense in the ADC map. Meanwhile, the …
Mapping of motor function with neuronavigated transcranial magnetic stimulation: a review on clinical application in brain tumors and methods for ensuring feasible …
… life for patients with malignant glioma as the prominent entity of intra-axial brain tumors [13,14,15,16,17,18].
To maximize the EOR while keeping surgery-related decline of function (eg, …
To maximize the EOR while keeping surgery-related decline of function (eg, …
[HTML][HTML] Deep immune profiling reveals targetable mechanisms of immune evasion in immune checkpoint inhibitor-refractory glioblastoma
EF Simonds, ED Lu, O Badillo, S Karimi… - … for immunotherapy of …, 2021 - ncbi.nlm.nih.gov
… patients, metacluster frequencies for each primary tumor were fed into the t-stochastic neighbor
embedding (t-SNE) dimensionality reduction algorithm to produce a map of … The glioma …
embedding (t-SNE) dimensionality reduction algorithm to produce a map of … The glioma …
Value of dynamic contrast perfusion MRI to predict early response to bevacizumab in newly diagnosed glioblastoma: results from ACRIN 6686 multicenter trial
KM Schmainda, MA Prah, H Marques, E Kim… - Neuro …, 2021 - academic.oup.com
… Treatment response for groups stratified by pretreatment … Of these, one-third are malignant,
of which 80% are gliomas. … across patients, NAWM was selected by one person (MAP) …
of which 80% are gliomas. … across patients, NAWM was selected by one person (MAP) …
[HTML][HTML] Immune checkpoint targeted therapy in glioma: status and hopes
… malignant glioma remain unknown, as the low response and persistence of treatments in
glioma … Given this, individualized treatment and real-time monitoring of treatment response are …
glioma … Given this, individualized treatment and real-time monitoring of treatment response are …
Anti‐tumour immune response in GL261 glioblastoma generated by Temozolomide Immune‐Enhancing Metronomic Schedule monitored with MRSI‐based …
S Wu, P Calero‐Pérez, L Villamañan… - NMR in …, 2020 - Wiley Online Library
… GL261 mouse glioma cells were obtained from the Tumour … responding to treatment, and
for calculating nosologic maps … work, we observed a transient therapy response to IMS-TMZ …
for calculating nosologic maps … work, we observed a transient therapy response to IMS-TMZ …
Glioblastoma: clinical presentation, diagnosis, and management
… tissue, and cortical mapping in awake patients.Tumour specimens … glioblastoma diagnosis
and monitor treatment response? … neurocognitive dysfunction in patients with diffuse glioma: a …
and monitor treatment response? … neurocognitive dysfunction in patients with diffuse glioma: a …
Decipher the glioblastoma microenvironment: the first milestone for new groundbreaking therapeutic strategies
GN Fanelli, D Grassini, V Ortenzi, F Pasqualetti… - Genes, 2021 - mdpi.com
… Malignant gliomas typically contain both neoplastic cells and … ; and (iii) glioblastoma NOS,
for which full IDH evaluation … differ in prognosis and therapy response. Primary glioblastomas …
for which full IDH evaluation … differ in prognosis and therapy response. Primary glioblastomas …
Current landscape and emerging fields of PET imaging in patients with brain tumors
… ), the assessment of treatment response to systemic treatment options such as … response
to antiangiogenic therapy with bevacizumab in patients with recurrent malignant glioma…
to antiangiogenic therapy with bevacizumab in patients with recurrent malignant glioma…
Response to trametinib treatment in progressive pediatric low-grade glioma patients
F Selt, CM van Tilburg, B Bison, P Sievers… - Journal of Neuro …, 2020 - Springer
… dose reduction and treatment response. The severity of the AEs resulted in discontinuation
of treatment in 2/18 (11%) patients (acneiform rash in both cases). No treatment related death …
of treatment in 2/18 (11%) patients (acneiform rash in both cases). No treatment related death …